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Epidermolysis bullosa (EB) is a genetic blistering disorder characterized by
intense pain related to disease pathology and care-based interventions. Opioid-
based therapies underpin pain care in EB; however, they are unable to provide
adequate analgesia in a significant proportion of patients. Cannabinoid-based
medicines (CBMs) have been studied increasingly for pain conditions of various
aetiologies and pose as a novel dimension for pain care in EB. We present three
patients with EB who were prescribed pharmaceutical-grade sublingually admin-
istered CBMs comprising tetrahydrocannabinol and cannabidiol. All three patients
reported improved pain scores, reduced pruritus and reduction in overall
analgesic drug intake.
What’s already known about this topic?
• Pain is the most burdening symptom for patients suffering from severe epidermol-
ysis bullosa (EB). Patients are exposed to numerous drug interventions, including
high-dose strong opioids, which often do not provide adequate analgesia and may
induce adverse effects.
• Cannabinoid-based medicines (CBMs) have been investigated for pain of various
aetiologies and show promise through their interaction with the endocannabinoid
system localized to central pain circuits.
• Cannabidiol has been reported to reduce wound pain in children with EB.
What does this study add?
• The prescription of sublingually administered pharmaceutical-grade CBMs may add
additional value to pain-care in EB and should be further investigated.
Pain is the most debilitating symptom in adults with epider-
molysis bullosa (EB), caused by mucocutaneous blistering,
wound care and medical interventions, and in the long term
is exacerbated by psychological and central sensitization. The
prevalence of pain in EB is 59–93% across subtypes,1 and
leads to significant distress and poor quality of life.2 The chal-
lenging management of pain in EB is characterized by a note-
worthy consumption of pain medication. Opioids underpin EB
pain care starting as early as infancy; however, they are con-
sidered problematic due to developing tolerance, dependence,
opioid-induced hyperalgesia, hormonal changes and obstipa-
tion. This concerns both patients with EB and caregivers, and
urges a pursuit for alternative treatments.
In the Netherlands, the prescription of pharmaceutical-grade
cannabinoid-based medicines (CBMs) containing tetrahydro-
cannabinol (THC) and cannabidiol (CBD) for pain has continu-
ally increased since becoming medically available in 2003.3 The
use of CBMs for pain in EB is discussed increasingly,4 yet
remains unexplored territory. Here we report anecdotal outcomes




A 64-year-old woman (EB012-01) diagnosed with junctional EB
generalized intermediate (JEB-gen intermed) suffered from
refractory pain for over 20 years, reporting 9/10 for pain on the
visual analogue scale (VAS). Her daily pain therapy included 39
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1000 mg paracetamol, 2 9 10 mg oxycodone extended release
(ER), 1 9 10 mg codeine-phosphate, 2 9 25 mg amitriptyline
and 19 5 mg g1 topical morphine (applied to the painful right
heel). However, this regimen could not provide satisfactory
analgesia. Ten years prior, she attempted treatment with an
inhaled CBM; however, she experienced only short-lived analge-
sia (< 45 min), and the presence of euphoria and dizziness. Sub-
sequently an orally administered CBM tea was prescribed with
no adequate pain relief.
Sublingual CBM oil (20 mg mL1 CBD, 13 mg mL1 THC)
was started at 05 mg CBD and 0325 mg THC, 4 9 daily and
increased stepwise up to 25 mg CBD and 1625 mg THC, 4 9
daily. She reported VAS scores ranging between 1/10 and 4/10.
At 3 months, she was weaned off oxycodone-ER and at 6
months, oxycodone immediate-release (IR) was used for dress-
ing changes only. During the following 2 years, treatment with
topical morphine was replaced with 1 mg CBD and 065 mg
THC CBM oil, applied daily to her painful heel; she was also
weaned off amitriptyline. Notably, she also reported a moderate
reduction of pruritus expressed by a lower pruritus frequency
and reduced urges to scratch. An increased appetite was the only
side-effect reported from the CBM, and she currently maintains
that this treatment provides adequate pain relief.
Case 2
A 41-year-old man (EB132-01) diagnosed with JEB-gen inter-
med was treated for pain, for over 10 years, with 1000 mg
paracetamol, 4 9 200 mg ibuprofen, 20 mg oxycodone-IR
and 5 mg g1 topical morphine, daily. He reported a VAS for
pain of 9/10 and sought alternative analgesic modalities. He
was therefore started on treatment with a sublingual CBM (20
mg mL1 CBD, 13 mg mL1 THC). At 1 month he reached a
dose of 3 mg CBD and 195 mg THC, 4 9 daily and reported
a VAS for pain of 3/10. He was weaned off oxycodone-IR
and topical morphine was stopped. Additionally, after com-
mencing the CBM treatment, he reported a reduction in the
frequency and intensity of his pruritus, as well as a reduced
urge to scratch. At 6 months, due to an increase of wound
pain, supplementary treatment was started with 5 mg oxy-
codone-IR 3 9 daily, subsequently inducing a self-reported
distorted sense of time and delayed reaction time. On the
grounds of a drug–drug interaction, the CBM was reduced to
nocturnal doses only, which alleviated these symptoms and
his pain relief was maintained. He stopped CBM treatment 2
months later as his health insurance withdrew reimbursement
of the sublingual CBM oil, which he could not afford (€200
per month). He was admitted to hospital after a subsequent
exacerbation of skin ulcerations and pain, whereby his clinical
team resorted to treatment with prednisolone 15 mg daily for
2 weeks, which provided only moderate analgesia. His pain
treatment remains unresolved.
Case 3
A 36-year-old man (EB015-01) diagnosed with recessive dys-
trophic EB generalized severe (RDEB-gen sev), had a history
of complications including chronic pain, pruritus, obstipation,
pseudosyndactyly, squamous cell carcinoma (SCC) of his
hands, and multiple amputations. His pain treatment consisted
of topical morphine, oxycodone-ER, oxycodone-IR, amitripty-
line, paracetamol, etoricoxib and locally injected dexametha-
sone. He experienced sedative side-effects from amitriptyline,
delayed wound healing by topical morphine, and obstipation
due to oxycodone-ER, oxycodone-IR and etoricoxib. Unable
to tolerate these side-effects, he experimented with CBM-flos
(the dried flower of the female cannabis plant) by way of
combustion and inhalation. During routine clinical follow-up
he reported an improvement of pain treated with paracetamol
and inhaled CBM-flos and his opioid-induced obstipation
resolved.
After 6 months, worsening tumour pain in both hands
required supplementary analgesia. As EB pain recommenda-
tions indicated the use of strong opioids, which were con-
traindicated due to his susceptibility to side-effects, a
sublingual CBM oil (20 mg mL1 CBD, 13 mg mL1 THC)
was started. At 1 week he reported a 40% reduction in pain
intensity. Both the sublingual CBM and intrapulmonary CBM
were continued for 2 years. The combination of intrapul-
monary and sublingual CBMs surpassed previous pain treat-
ments, and additionally reduced the severity of pruritus and
his urge to scratch.
Later, he entered terminal care as a sequela of metastasized
cutaneous SCC and persisted to continue both intrapulmonary
and sublingual CBM administration, combined with 10 mg
amitriptyline and 10 mg prednisolone, daily. He died at 38
years of age.
Discussion
Pain in EB significantly impacts quality of life and day-to-day
functioning.1,5 In addition to nociceptive pain associated with
blistering and wounds, peripheral nerve damage objectified in
RDEB,6 and postulated in JEB, adds plausibility to reported
high pain scores in these EB types.7 Neuropathies limit the
central role of opioids for EB pain as they may be less effec-
tive for this type of pain according to systematic analysis.8
The persistent inflammatory condition in RDEB skin may
also contribute to central sensitization to painful stimuli,6
which is challenging to objectify through diagnostic tech-
niques, and does not respond adequately to targeted thera-
pies.9 The different aetiologies of pain in EB require
tailored interventions and therefore pain care is optimized
through combined drug treatments and psychological inter-
ventions. However, the limited effectiveness of conventional
analgesics stresses the fact that the gold standard for pain
care in EB has yet to be established, hence motivating clini-
cians to consider alternative treatments for EB pain from
various aetiologies.
All three patients were prescribed CBMs, comprising THC
and CBD, by way of sublingual administration, with good
effects. However, two patients had used at least one other
administration form of which one patient had administered
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self-acquired CBMs. Studies on CBM treatments show vary-
ing levels of success with moderate-quality evidence sup-
porting CBM efficacy for chronic pain.10 In general, the
difficulty of measuring clinical outcomes of CBM treatments
is characterized by numerous administration forms and
cannabinoid compositions. This has led to a call for the
production and distribution of standardized, pharmaceutical-
grade, CBM compositions and administration forms which
can increase the predictability of dosing and effects as well
as reducing the hazards of over- and underdosing, in the
clinical setting.11
Cannabinoids mimic the actions of endocannabinoids,
endogenous ligands, which play a key role in synaptic trans-
mission. Pain modulation has been a central point of discus-
sion, explained, among other reaons, by the actions of
cannabinoids on neuronal circuits through cannabinoid-bind-
ing receptor (CB) dependent and independent pathways.12
CB1 and CB2 are expressed on presynaptic terminals of pri-
mary afferent pain circuits, brain areas processing nociception,
including the central–medial thalamic nuclei, periaqueductal
grey and raphe nuclei, and are colocalized with l-opioid
receptors in the spinal cord junction for peripheral nociceptive
neurons. The role of CB2 antinocinception has also been
implied in inflammatory and neuropathic pain models, likely
due to the interaction of the endocannabinoid system with
endorphin/enkephalin, vanilloid/transient receptor potential
and inflammatory systems.13 CB1/2 have been localized in
human skin, and CB2 activation on keratinocytes is described
to produce antinociception through the peripheral release of
endogenous opioids.13
Pruritus entails the largest physical and psychological bur-
den for children with EB,2 and the reported diminished fre-
quency and intensities of pruritus in these cases is notable as
the antipruritic effects of CBMs have been postulated in several
dermatological conditions.14
In these cases, patients were prescribed a combination of
THC and CBD, which are the most studied plant-based
cannabinoids (phytocannabinoids). THC, like the endo-
cannabinoids 2-arachyldonylglycerol and anandamide, is a
partial agonist of CB1/2 and has been shown to stimulate
b-endorphin production, allowing for opioid sparing in clini-
cal practice.15 CBD, in contrast to THC, has a low affinity for
CB1/2, and at high doses does not produce psychotropic
effects.13 Interestingly, CBD is able to antagonize undesired
effects of THC such as sedation and intoxication while concur-
rently improving desirable effects like analgesia.13
Although the therapeutic potential of CBMs in pain control in EB
is interesting, one cannot exclude the effect of placebo on patient-
reported changes. In addition to this, core aspects of CBM thera-
peutics include the sufficient expression of CB1/2, which in EB is
unknown. These limitations warrant further investigations of CBMs
in controlled study settings in order to objectify the reported pain
changes observed in these cases, and close the gap between current
treatment standards and patient needs.
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